Patient, caregiver, and provider reported risk-benefit acceptance thresholds in non-muscle invasive bladder cancer (NMIBC) trial designs.

424Background: FDA guidelines for NMIBC clinical trial design have stimulated a marked increase in NMIBC trial conduct. However, NMIBC patient (PT) input to define acceptable treatment toxicity thr...